Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma, Mantle-Cell 2Lymphoma 2Colonic Neoplasms 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocythemia, Essential 1Somatostatinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pituitary Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Growth Hormone-Secreting Pituitary Adenoma 1Congenital Abnormalities 1Colorectal Neoplasms 1

Interventions

Gemcitabine 54Specimen Handling 16Fluorouracil 15Radiotherapy 13Biopsy 12Oxaliplatin 10Magnetic Resonance Spectroscopy 10Erlotinib Hydrochloride 10Cyclophosphamide 10aldesleukin 8fludarabine 7Bevacizumab 7sargramostim 6Radiation 6veliparib 5Trastuzumab 5Leucovorin 5Cetuximab 5Capecitabine 5Taxes 4Sunitinib 4Irinotecan 4HhAntag691 4Cisplatin 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4tipifarnib 3rubitecan 3entinostat 3X-Rays 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pancreatic Neoplasms × Biological Therapy × Clear all
NCT00253526 2015-04-28

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡